Navigation Links
Vaccinex Antibody Licensed to GlaxoSmithKline
Date:2/15/2008

ROCHESTER, N.Y., Feb. 15 /PRNewswire/ -- EUSA Pharma (Oxford, UK), a Vaccinex collaboration partner, has announced that it has licensed OP-R003, a human anti-interleukin-6 antibody discovered by Vaccinex, to GlaxoSmithKline.

According to the terms of the product license, GSK will pay an up-front license fee, development milestones, and royalties on product sales to acquire the exclusive world-wide rights to develop and commercialize OP-R003 for the treatment of rheumatoid arthritis and other disease indications. Vaccinex will share 50% of fees, payments and royalties. The antibody was discovered by Vaccinex utilizing its ActivMAb(R) antibody discovery technology and first licensed for co-development by EUSA Pharma (formerly OPi SA).

"We are pleased that our collaboration in the discovery and co-development of OP-R003 has attracted such a world-class partner as GSK. Together with previously announced antibody partnerships with Biocon, Ltd. and Teva Pharmaceutical, this transaction further validates the quality of human antibodies selected with Vaccinex's ActivMAb(R) antibody discovery technology," remarked Dr. Maurice Zauderer, Vaccinex's President and CEO.

Commenting on the acquisition, Brian McVeigh, GSK's Worldwide Business Development Director of M&A Strategy and Transactions, said, "Interleukin-6 is increasingly recognized as an important biological target in a range of diseases, and consequently OP-R003 has great potential to meet a number of unmet medical needs."

About Vaccinex

Vaccinex, Inc. is a biotechnology company engaged in the discovery and development of human monoclonal antibodies and other biologics to treat a variety of serious illnesses, including autoimmune disease, inflammation, multiple sclerosis, and cancer. The company's patented ActivMAb(R) technology allows for the direct selection of high affinity, fully human monoclonal antibodies that would be difficult or impossible to identify using other system
'/>"/>

SOURCE Vaccinex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vaccinex, Inc. Announces Award of Key Patent in Europe for its Antibody Discovery Technology (ActivMab(R))
2. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
3. Human Genome Sciences and Xencor Announce Antibody Collaboration
4. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
5. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
6. Roche Files IND for Second Genmab Antibody
7. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
8. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
9. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
10. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
11. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... Lighthouse Information Systems, Inc., a West ... Oregon, Washington and clients across the US, announces ... (M&A) Integration Services offering, effective immediately. ... M&A Integration Practice Leader at Lighthouse, explains, “Research ... M&A initiatives fail to achieve their intended economic ...
(Date:3/30/2015)... , March 30, 2015  Heidrick & Struggles (Nasdaq: ... leadership consulting and culture shaping worldwide, ... firm to lead its global Healthcare and Life Sciences practice. ... Life Sciences, Mitchell will lead a team of more than ... Europe and Asia serving ...
(Date:3/30/2015)... March 30, 2015 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a commercial focus on China ... Administration (CFDA) has approved the Company,s application to conduct ... cell carcinoma (OCCC) patients for its proprietary drug candidate ...
(Date:3/30/2015)... CARDIFF, UK, and BELLINGHAM, Washington, USA (PRWEB) March 29, ... energy projects in Europe and the United States and ... programme highlights planned for SPIE Optics + Optoelectronics ... will feature over 700 technical presentations in 17 conferences ... international society for optics and photonics , the event ...
Breaking Biology Technology:Lighthouse Information Systems, Inc., Announces Addition of M&A Integration Services 2Heidrick & Struggles Strengthens Leadership of Healthcare - Life Sciences Practice 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3
... DIEGO, Sept. 13 Genomatica announced today ... the company full time as executive chairman and chief ... with leading chemical producers, users, feedstock suppliers, brands and ... and biotech leadership; $500 million in partnerships ...
... Convergent Procedure, a novel approach to treat atrial ... nContact Surgical, Inc. (nContact), was highlighted at the ... Association for Cardio-Thoracic Surgery) Annual Meeting in Geneva, ... 2010 Techno-College Programme to receive an update on ...
... Berkeley, have developed a pressure-sensitive electronic material from semiconductor ... the term "thin-skinned." "The idea is to ... which means incorporating the ability to feel and touch ... and computer sciences and head of the UC Berkeley ...
Cached Biology Technology:Bill Baum Joins Genomatica as it Ramps for Commercial Rollout 2Bill Baum Joins Genomatica as it Ramps for Commercial Rollout 3Bill Baum Joins Genomatica as it Ramps for Commercial Rollout 4The Convergent Procedure for the Treatment of Chronic Atrial Fibrillation Highlighted at EACTS Annual Meeting in Geneva 2Engineers make artificial skin out of nanowires 2Engineers make artificial skin out of nanowires 3
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided ...
(Date:3/17/2015)... , March 17, 2015 MedNet ... specializing in clinical study management systems, is pleased ... attendance at ARENA,s Outsourcing in Clinical Trials Southeast ... event provides an excellent forum for MedNet to ... and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/16/2015)... 2015 Between 16 and ... groundbreaking innovations in biometric identification at the CeBIT ...      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ) ... well at the forefront: the company,s all new ... Germany . BiometricGate is the ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
... Researchers at the RIKEN Plant Science Center (PSC) have ... in the model plant Arabidopsis protects cells from harmful ... the journal PLoS Genetics , the finding contributes ... biological processes in both plants and animals, opening the ...
... seals often encounter murky water that impedes their vision; ... Extending their vibration-sensitive whiskers, the mammals are almost as ... if guided by sight. Wolf Hanke and his colleagues ... how harbour seals perceive the world through their flow-sensitive ...
... 2011 UT Southwestern Medical Center researchers have discovered a ... to a treatment to keep cancer cells from spreading. ... 1 (Rasip1) is so specific and central to so many ... form, said Dr. Ondine Cleaver, assistant professor of molecular biology ...
Cached Biology News:Discovery of DNA silencing mechanism reveals how plants protect their genome 2Seals sense shapes using their whiskers to feel wakes 2UT Southwestern researchers find protein that might be key to cutting cancer cells' blood supply 2